Stephen J. Ubl @steveubl Twitter profile

Last Seen Profiles

@lvcidia

@chvampagne

@chagurock

@rwzeidan

@stw_pdg

@I_Leak_VN

@ImadChoueiry

@TupSoftball

@umalatovmma

@FulhamLillies

@Laila___a

@SaKrabbe

@PrepRedzoneNE

@MarceloBot

@__betavulgaris

@helicoptero2024

@gjbb1033

@Vvv023vvv

@heatherpiperxo_

@ginirohagiwara2

@Dr_NohaHassan

@CYN_THIAX

@mia_asianart

@wearekiligs

@Antoniho5

@Banderadesuecia

@calcioinglese

@sanggalaja

@Akon52600821

@appropedia

@enyaville

@BlueDevilCenter

@Kev_elmazi

@Boysinundiess

@IsraelinChicago

@LisaTak19616629

Stephen J. Ubl

@steveubl

4 years

Today, there are 18 vaccines against COVID-19 in clinical trials & over 130 vaccines in preclinical studies. Not all of these will succeed, so it’s important to have as many shots on goal as possible. Learn the latest on the industry's progress here:

Check out how PhRMA member companies are helping in the fight against COVID-19

America’s biopharmaceutical companies are committed to developing solutions to help diagnose and treat those with COVID-19, caused by a novel strain of coronavirus.

phrma.org

2K

3K

10K

Stephen J. Ubl

@steveubl

4 years

I joined Giovanni Caforio, M.D., chairman of the board and CEO at @bmsnews , in penning this open letter about how our industry is working non-stop to find effective treatments and vaccines.

538

2K

6K

Stephen J. Ubl

@steveubl

11 months

While the #CancerMoonshot aims to wage a war on cancer, it appears to me that the Biden administration has waged a war on the cure instead through a series of policies that stifle innovation and access. Read more in my @statnews op-ed:

Biden promised a ‘war on cancer’ — but declared war on the cure instead

Ending cancer is an achievable goal, but new Biden administration policies are standing in the way, says PhRMA’s CEO and president.

www.statnews.com

458

1K

5K

Stephen J. Ubl

@steveubl

4 years

I’m pleased to share a first look at our new TV ad showing how the biopharmaceutical industry is doing its part to get our world back to normal through research & development.

223

604

4K

Stephen J. Ubl

@steveubl

4 years

#Coronavirus didn't find us flat-footed: Our companies are prepared for public health crises due to decades of investment, preparedness & work on similar viruses. Proud to stand next to @GileadSciences @Merck @JNJNews & @SanofiUS & discuss how we're developing vaccines/treatments

758

510

3K

Stephen J. Ubl

@steveubl

6 years

. @bobjherman : of U.S. health care spending, ~10% is retail drug spending while hospitals/doctors is ~50%. This article is an eye opener into the disproportionate focus on what contributes to the high cost of health care.

Think drug costs are bad? Try hospital prices

Hospitals aren't following pharma's symbolic pricing moves.

www.axios.com

201

2K

3K

Stephen J. Ubl

@steveubl

8 months

The Inflation Reduction Act is forcing biopharmaceutical companies to rethink investment, with the government essentially picking winners and losers by discouraging the development of some types of medicines and treatments for certain patient populations.

296

836

3K

Stephen J. Ubl

@steveubl

4 years

Proud to join my @phrma colleagues in this video series that covers how the biopharmaceutical industry is working to develop safe and effective #COVID19 vaccines

COVID Experts

phrma.org

536

640

3K

Stephen J. Ubl

@steveubl

4 years

Three of our member companies established programs so their employees with medical/lab expertise can volunteer to help local health care organizations. Hear from four employees who are answering the call to help their communities: @LillyPad @Merck @pfizer

Lilly, Merck and Pfizer empower team members to volunteer on COVID-19 frontlines

As biopharmaceutical companies continue to fight COVID-19 through research and development, three companies have teamed up to create programs empowering employees with medical and laboratory expert...

phrma.org

76

652

3K

Stephen J. Ubl

@steveubl

6 years

In my @USATODAY opinion piece I explain why providing a drug's list price in ads could be confusing w/out proper context. We'll link to info disclosing list price, potential out-of-pocket costs & available financial assistance. This is a win for patients.

PhRMA: Drug list prices in ads would be confusing

We want to provide cost information in a comprehensive fashion, writes Stephen J. Ubl, CEO of Pharmaceutical Research and Manufacturers of America.

www.usatoday.com

400

493

2K

Stephen J. Ubl

@steveubl

6 months

The U.S. leads the world in the development of new treatments and cures because our system enables the private sector to collaborate with government and academic research centers for the benefit of patients. Today's proposal by the Biden Administration to seize patents will mean

233

394

2K

Stephen J. Ubl

@steveubl

4 years

Our industry is collaborating with regulators and health care orgs worldwide to develop solutions to diagnose and treat #Coronavirus . More than half of @PhRMA members have R&D efforts underway or are donating medicines/medical supplies/financial support.

298

319

2K

Stephen J. Ubl

@steveubl

2 years

Physicians should determine what’s best for patients – not middlemen. But the top 3 PBMs now restrict formulary access to a total of 1,150+ medicines, according to a new report from @Xcenda . Time to bring more accountability to these middlemen.

Skyrocketing growth in PBM formulary exclusions continues to raise concerns about patient access

www.xcenda.com

31

363

2K

Stephen J. Ubl

@steveubl

6 years

Today I announced the industry’s bold new step of saying PBMs & other entities in the supply chain should no longer be paid off the list price of a medicine. The status quo is not working in the best interests of patients and it’s time to break the chain of misaligned incentives.

37

196

1K

Stephen J. Ubl

@steveubl

2 years

A @JAMAInternalMed study finds hospitals mark up medicines by as much as 634%, which leads to higher out-of-pocket costs for patients. This is further proof that we need to look across the system to lower Rx costs.

Hospitals' massive cancer drug markups

Negotiated prices with insurers are often double what the hospital paid to acquire the drug, according to a new study.

www.axios.com

71

492

1K

Stephen J. Ubl

@steveubl

3 years

A year ago, @WHO declared #COVID19 a global pandemic. Leaders from @LillyPad and @TakedaPharma join me in reflecting on the past year and our industry's nonstop work to find effective treatments and vaccines.

One Year Into The Pandemic: An Update From Leaders

null

www.youtube.com

69

86

1K

Stephen J. Ubl

@steveubl

8 months

The Cancer Moonshot is an inspiring goal, but it requires the right policies to succeed. That's why leaders across the R&D ecosystem voiced concerns about policies from the Biden Administration that are making the fight against cancer more challenging.

R&D leaders to Biden Administration: Your policies are undermining the Cancer Moonshot

As industry research and development leaders warn in a new letter to the Biden Administration, the Cancer Moonshot might have to call off its mission before it can get off the ground.

phrma.org

63

183

1K

Stephen J. Ubl

@steveubl

7 years

"Lives Depend on a Fair Trade Protecting US Medical Innovation.” Read my piece in today’s @RealClearHealth

44

336

850

Stephen J. Ubl

@steveubl

7 years

Great News! @PhRMA & @ACSCAN report shows 240+ immuno-oncology meds/vaccines in development for cancer. #GoBoldly

More than 240 immuno-oncology treatments in development to fight cancer

A new report shows there are more than 240 immuno-oncology medicines and vaccines in development to treat cancer.

phrma.org

61

299

811

Stephen J. Ubl

@steveubl

5 years

Death rates from cancer have decreased 27% after peaking in 1991. This #WorldCancerDay , I’m heartened by the fact that 16 of the 59 novel @US_FDA approvals in 2018 were oncology medicines.

23

178

842

Stephen J. Ubl

@steveubl

1 year

Check out our new TV ad showing how middlemen are getting between patients and the medicines they need. We need real PBM reform that addresses the challenges people face every day at the pharmacy.

22

225

871

Stephen J. Ubl

@steveubl

8 months

We worked with @TheRoot to dig into alarming findings from our recent Patient Experience Survey. Health insurance isn’t working like it should – particularly for historically underserved communities. We all need to work together to improve access to care.

Survey Shows Health Coverage Falls Short For Insured Black Americans

Medical advocacy group PhRMA reports that issues including high out-of-pocket costs prevent insured patients from receiving the healthcare they need.

www.theroot.com

48

145

754

Stephen J. Ubl

@steveubl

4 years

I recently spoke to @AlbertBourla about a potential COVID-19 vaccine @Pfizer is working on consisting of mRNA. One potential benefit of mRNA vaccines is that they may offer greater flexibility and do not require viral material at all. More here:

Coming together to fight COVID-19: A conversation with Albert Bourla, Chairman & CEO of Pfizer, Inc.

Over the last six months, our industry has been working around the clock to combat the COVID-19 virus, including developing potential therapeutics to treat COVID-19 and vaccines to prevent future...

phrma.org

204

191

611

Stephen J. Ubl

@steveubl

4 years

We need public confidence in #COVID19 vaccines for them to be effective. That’s why our industry is meeting the highest standards, providing transparency and advancing clinical trial diversity. Read my latest @statnews piece to learn how we're doing this

What the biopharma industry is doing to build confidence in Covid-19 vaccines

The approach to Covid-19 — putting safety first, being open and transparent, and working to ensure diverse representation in clinical trials — is a model for the future of biopharmaceutical innovat...

www.statnews.com

334

90

561

Stephen J. Ubl

@steveubl

7 years

Given the scope of the #opioidcrisis , we believe supporting policies for 7-day script limit on opioids is right thing to do. #drugcommission

121

141

577

Stephen J. Ubl

@steveubl

4 years

Yesterday, leading researchers from our member companies gathered in DC to discuss our industry’s response to #coronavirus . The industry is uniquely positioned to develop a vaccine & find a treatment for those infected. Read more. via @LinkedIn #covid19

In Pursuit of Coronavirus Treatments and Vaccines

Yesterday, I joined leading executives and researchers from four of our member companies to discuss our industry’s response to fighting COVID-19, a novel form of the coronavirus. Our companies are...

www.linkedin.com

125

127

501

Stephen J. Ubl

@steveubl

2 years

Rationing insulin can have devastating effects. We're pushing for changes to improve the system, but there is also help available for those who can't afford their insulin, including for those w/o insurance. Visit to see what assistance may be available.

26

134

487

Stephen J. Ubl

@steveubl

11 months

Keysha - who credits clinical trials with saving her husband's life - is a great example of why we must keep fighting to enhance diversity in clinical trials. Learn more about our community-based approach from our recent collaboration with the @nytimes .

PAID POST by PhRMA — Knocking Down Systemic Barriers

Supported by a grant from PhRMA, Equitable Breakthroughs in Medicine Development is a first-of-its-kind collaboration to increase participation by people of color in clinical trials.

www.nytimes.com

30

85

485

Stephen J. Ubl

@steveubl

6 years

Another solution we've brought to the table that will help patients at the pharmacy counter: Take billions in rebates, discounts negotiated annually & give to patients instead of further padding profits of health plans & PBMs with more government business.

PhRMA Statement on HHS Speech and Part B Proposal

www.phrma.org

28

121

381

Stephen J. Ubl

@steveubl

5 months

By now, we’ve all read the #JPM24 hot takes. Now it’s time to figure out how that readout of the news shared in San Francisco translates to the policy agenda in Washington.

When it comes to the future of innovation, the ball is in policymakers’ court

We have next-generation treatments. Now, patients need next-generation approaches to access.

phrma.org

7

38

451

Stephen J. Ubl

@steveubl

4 years

Read about 11 principles @PhRMA and @IAmBiotech committed to in order to help those affected by this pandemic. Together, we will succeed in finding effective vaccines and treatments.

America’s biopharmaceutical companies are working around the clock to beat coronavirus

PhRMA and BIO underscored the industry’s commitment to finding solutions to prevent, diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. The investments...

phrma.org

115

60

367

Stephen J. Ubl

@steveubl

2 years

Thank you to the thousands of researchers who continue to help protect patients from COVID-19. The lessons learned will guide policymakers, patients, caregivers and health care providers to make more informed decisions regarding the future of health.

ICYMI: New resource catalogs biopharmaceutical industry lessons learned from COVID-19

In a new resource released by PhRMA, here are some key lessons learned from the more than two years of dedicated efforts to fight COVID-19.

phrma.org

19

72

356

Stephen J. Ubl

@steveubl

5 years

New @CMSGov NHE data show last year: - Physicians/clinical services spending grew 4.1% - Hospital spending grew 4.5% - Retail medicine spending grew just 2.5% - Prices for retail meds fell 1% We need to look across the entire health care system to address patient affordability

17

55

305

Stephen J. Ubl

@steveubl

2 years

When insurers use accumulator adjustment programs, it forces patients to pay more out of pocket, steering them away from their prescribed medicines and toward worse health outcomes. Read more about how insurers get between patients and their medicines:

404

phrma.org

12

131

291

Stephen J. Ubl

@steveubl

11 months

Our latest survey of 5000+ insured Americans shows that insurers and their PBMs are making it harder for people to get the medicines they need. It should be no surprise that overwhelming majorities support policies that hold them accountable.

13

70

286

Stephen J. Ubl

@steveubl

4 years

Today’s news is historic. Our industry has put unprecedented effort toward developing #COVID19 vaccines. While today is just one step, I am proud of the work @pfizer has done to achieve this important milestone in our fight against #COVID19 .

52

41

249

Stephen J. Ubl

@steveubl

5 years

Pleased to announce @genentech & @GileadSciences have joined @PhRMA . We represent cos committed to making the promise of science a reality. I look forward to having them at the table as we engage w/ stakeholders on pragmatic, pro-consumer policy solutions.

PhRMA Welcomes Genentech and Gilead Sciences to Association

I’m pleased to announce that Genentech and Gilead Sciences, Inc. have joined the Pharmaceutical Research and Manufacturers of America (PhRMA).

www.linkedin.com

29

51

233

Stephen J. Ubl

@steveubl

7 years

#Opioidabuse a national public health crisis. @POTUS @GovChristie & @NIHDirector are to be commended for urgency & attention on this matter.

67

60

224

Stephen J. Ubl

@steveubl

6 years

I spoke at the opening segment of the annual Aspen Ideas Festival #SpotlightHealth regarding the future of medicine. Here are my thoughts: #GoBOLDLY

Aspen Ideas Festival #SpotlightHealth: Sustaining Innovation, Affordability and the Future of...

This weekend I spoke on a panel at Spotlight Health – the opening segment of the annual Aspen Ideas Festival – about the future of medicine. While we didn’t agree with each other 100 percent of the...

www.linkedin.com

11

45

215

Stephen J. Ubl

@steveubl

7 months

Wonderful discussion by @Genentech ’s Joy Russell and @Politico on the importance of addressing disparities in health care. As an industry, we must all work to level the playing field and achieve a more equitable health care system.

Sponsored Content: Dismantling Health Disparities

Dismantling health disparities: Why purpose-driven partnerships are key to achieving health equity. @PhRMA sponsored content on @POLITICO.

www.politico.com

12

27

238

Stephen J. Ubl

@steveubl

6 years

According to @CMSGov , spending on retail medicines grew by just 0.4 percent last year, substantially less than hospital spending growth (4.6%) and physician & clinical services spending (4.2%). This is the slowest growth rate since 2012.

19

51

215

Stephen J. Ubl

@steveubl

2 years

49% of insured Americans who take prescription medicines face insurance practices that stood between them and their medicines. We need to make insurance work like insurance by removing barriers to care so patients can access the medicines they need.

Covered By Insurance But Still Exposed Barriers to Care for Insured Americans

phrma.org

11

68

225

Stephen J. Ubl

@steveubl

4 years

Our industry continues to fight back against #COVID19 and its impact on mental health. I recently sat down with Peter Anastasiou, EVP of @Lundbeck , to talk about these two health crises.

Coming together to fight COVID-19: A conversation with Peter Anastasiou, Executive Vice President...

A conversation with Peter Anastasiou, Executive Vice President of Lundbeck and Steve Ubl, CEO of PhRMA.

phrma.org

44

34

177

Stephen J. Ubl

@steveubl

7 years

How do you negotiate better deals for prescription medicines? Read my thoughts in Forbes:

16

97

163

Stephen J. Ubl

@steveubl

5 months

Just 3 PBMs control 80% of the market. Their business model is rife with conflicts, and they game the system at the expense of patients. There’s a growing chorus of voices calling on Congress to #endPBMabuse and fix the system to help make sure patients pay less.

14

86

178

Stephen J. Ubl

@steveubl

2 years

The 340B program needs to be fixed. Nearly 60% of U.S. hospitals participate in it, but there is little to no evidence these hospitals use 340B to help vulnerable patients.

5

61

166

Stephen J. Ubl

@steveubl

4 years

In the midst of #COVID19 , affording your medicines may be more difficult right now. A year ago, @PhRMA 's member companies launched the Medicine Assistance Tool to connect patients with resources that may help lower out-of-pocket costs. Learn & share.

PhRMA’s Medicine Assistance Tool Celebrates One Year Helping Address Patient Affordability Challe...

While America’s biopharmaceutical companies are working around the clock to develop a treatment for COVID-19, companies are also expanding efforts to help patients access other medicines they need....

www.linkedin.com

16

37

153

Stephen J. Ubl

@steveubl

6 years

Our member companies are taking a new approach to how they communicate about medicines in DTC television advertisements in order to make it easier for patients to access information about medicine costs. 1/3

38

57

153

Stephen J. Ubl

@steveubl

2 years

A network of sustainable, community-based trial sites can go a long way in improving access to clinical trials and health equity, and that's just what Equitable Breakthroughs in Medicine Development is all about. Learn more about this effort:

8

26

133

Stephen J. Ubl

@steveubl

5 years

This week in @FortuneMagazine , @SanofiUS CEO Olivier Brandicourt & I discuss the best way to lower patient out-of-pocket costs: Share the $166 Billion in rebates & discounts given to middlemen in the supply chain w/ patients at the pharmacy counter. Read:

Commentary: Want to Lower Drug Costs for Patients? Start With Rebates

Commentary: Our current system encourages high list prices for prescription drugs. Trump plans to lower them by reforming rebates.

fortune.com

41

46

139

Stephen J. Ubl

@steveubl

6 years

Biopharma cos are working w/payers to move to a value-driven health care system where the focus is on outcomes that matter most to patients. This approach - a rare area of policy agreement - lowers out of pocket costs & enables patient access to the right treatments right away.

28

33

144

Stephen J. Ubl

@steveubl

7 years

New public/private partnership will bring together best minds from industry, @US_FDA & @NIH to address problem of prescription drug abuse.

28

50

126

Stephen J. Ubl

@steveubl

6 years

Great to see @Axios broadening the cost conversation. @BobJHerman ’s piece on high hospital costs & recent analysis showing hospitals marking up medicines ~500% demonstrate the role hospitals play in drug prices. Why do hospitals charge so much? Find out at

10

50

123

Stephen J. Ubl

@steveubl

7 years

The U.S. is recognized as the global leader of biopharma innovation. The new 2017 Industry Profile shows exactly why

3

32

117

Stephen J. Ubl

@steveubl

6 years

Under-reported fact: medicine cost grew just 1.5% in 2017, the slowest in 25 years ($ESRX data).

14

44

115

Stephen J. Ubl

@steveubl

6 years

Patient out of pocket costs are skyrocketing - deductibles are up 300% since 2006. Now, middlemen are implementing new programs which block coupons from being applied to deductibles, potentially resulting in patients paying thousands more at the pharmacy.

19

58

102

Stephen J. Ubl

@steveubl

2 years

30% of insured Americans face a financial barrier to care, such as unaffordable out-of-pocket costs or a lack of savings to pay for emergency or unforeseen expenses. It is time to address what is really driving up costs for patients.

Navigating the Patient Experience The Barriers and Burdens Standing Between Patients and Care

Navigating the Patient Experience: The Barriers and Burdens Standing Between Patients and Care is the third report of PhRMA’s Patient Experience Survey, a research initiative designed to explore the...

phrma.org

4

22

100

Stephen J. Ubl

@steveubl

2 years

. @PhRMA and our member companies are committed to building a more diverse and inclusive biopharmaceutical industry. As part of this commitment, we launched our Talent Community on @LinkedIn to help open pathways to our industry. Learn more:

Join PhRMA’s New Talent Community

I am excited to announce PhRMA's Talent Community on LinkedIn, aimed at helping talent find opportunities in the biopharmaceutical industry. Evidence shows that more diverse and inclusive workplaces...

www.linkedin.com

12

16

84

Stephen J. Ubl

@steveubl

5 years

Today in @Fortune , @SanofiUS CEO Olivier Brandicourt and I discuss the best way to lower patient out-of-pocket costs: Share the $166 Billion in rebates & discounts given to middlemen in the supply chain with patients at the pharmacy counter. More here:

Commentary: Want to Lower Drug Costs for Patients? Start With Rebates

Commentary: Our current system encourages high list prices for prescription drugs. Trump plans to lower them by reforming rebates.

fortune.com

15

24

92

Stephen J. Ubl

@steveubl

6 years

We are not for the status quo. We’ve come to the table w/ market-based reforms & one area we agree is testing value-based models that align reimbursement w/ patient outcomes. Foreign price controls takes our health care system in the opposite direction.

PhRMA Statement on HHS Speech and Part B Proposal

www.phrma.org

11

25

69

Stephen J. Ubl

@steveubl

7 years

After speaking w/ @POTUS #DrugCommission on #opioidcrisis , I'm announcing support for state & federal policies to address the growing crisis

18

23

73

Stephen J. Ubl

@steveubl

7 years

We believe @POTUS agenda on taxes, trade & regulations could create 350,000 American jobs over 10 years due to biopharma industry growth 2/3

23

61

59

Stephen J. Ubl

@steveubl

3 years

This isn’t the first time we’ve heard alarmist predictions about spending on new medicines that were off base. Wildly off base at times. Other dire warnings have missed the mark by an average of 550%.

(PDF) Systematic bias in predictions of new drugs' budget impact: analysis of a sample of recent US...

PDF | Objective: Expectations about the budget impact of new drug launches may affect payer behavior and ultimately consumer costs. Therefore, we... | Find, read and cite all the research you need on...

www.researchgate.net

7

12

60

Stephen J. Ubl

@steveubl

6 years

My outlook for 2018: Seeing incredible scientific breakthroughs, rapidly decelerating drug spending, broader discussion on supply chain, hospitals and other factors that bear on patient costs and momentum on market-based solutions. #JPM18 #JPMHC18

8

24

60

Stephen J. Ubl

@steveubl

6 years

We left the @JDRF Gala tonight with something special we didn’t expect! Proud to support an organization doing so much to improve the quality of life and ultimately find a cure for for those living with Type 1 diabetes.

3

4

53

Stephen J. Ubl

@steveubl

7 years

I'm excited to unveil our new #GoBoldly TV spot. This is not a video game. This is the destruction of a cancer cell.

4

47

50

Stephen J. Ubl

@steveubl

3 years

The events unfolding in our nation’s capital are appalling and violate the better values of our nation. It’s time for the peaceful transition of power our Constitution requires and the mob standing in the way must be condemned. 1/2

2

9

50

Stephen J. Ubl

@steveubl

7 years

In passing #PDUFA 94-1, the U.S. Senate voted to support patients, medical innovation & a stronger FDA. My full statement here:

1

26

50

Stephen J. Ubl

@steveubl

7 years

Six @PhRMA board members and I just had a positive, productive meeting w/ @POTUS & @VP to talk jobs, economy & health care. 1/3

7

51

50

Stephen J. Ubl

@steveubl

7 years

Wishing everyone a Happy Thanksgiving.

7

2

48

Stephen J. Ubl

@steveubl

5 years

I laud @POTUS ’ goal of ending #HIV infections within 10 years. America is a land of innovators & our biopharmaceutical scientists & researchers are working tirelessly to make this goal a reality. #SOTU

2

13

47

Stephen J. Ubl

@steveubl

6 years

This @nytimes article is welcome news - not just for lung cancer patients now but for cancer patients in future. #Immunotherapy treatments represent latest scientific developments promising to favorably change the outcomes of a cancer diagnosis #GoBOLDLY

3

27

47

Stephen J. Ubl

@steveubl

3 years

Grateful to be fully vaccinated and able to safely gather with friends and family to celebrate this Independence Day. I hope everyone has a #Happy4thofJuly . #July4th

12

5

48

Stephen J. Ubl

@steveubl

6 years

For some time we’ve been calling on middlemen – like PBMs & insurers – to share the savings they negotiate on drug costs with patients. @BruceJapsen ’s piece in @Forbes seems to indicate they’re getting the message.

UnitedHealth Group Will Pass Drug Maker Rebates Directly To Customers

UnitedHealth Group will pass along pharmacy discounts it gets from drug manufacturers from rebates via a new program for its full-insured customers at the point of prescription sale.

www.forbes.com

3

28

46

Stephen J. Ubl

@steveubl

5 years

Incredible @WSJ story. Michelle was near death yet with personalized cancer therapy she walked out of the hospital 24 hours later! Our researchers & scientists are working tirelessly to cure or turn cancer into a manageable chronic condition. #GoBOLDLY

New Cancer Drugs Aim to Offer Alternatives to Chemo

The treatments represent an emerging way of treating certain cancers—by targeting tumors based on their genetic characteristics, rather than their location in the body.

www.wsj.com

3

14

46

Stephen J. Ubl

@steveubl

9 months

The PBM business model keeps shifting to maximize profits and avoid policymakers' efforts toward transparency. A new @NephronResearch analysis shows PBMs are shifting their business model to rely on opaque fees and steering patients to pharmacies they own.

New analysis shows PBMs use fees as a profit center

Pharmacy benefit managers (PBMs) demand more than double the amount of fees today than they did five years ago, according to a new report from Nephron Research.

phrma.org

3

13

46

Stephen J. Ubl

@steveubl

6 years

PBMs & insurers receive more than $100B in rebates, but typically use list prices—rather than discounted prices—to determine how much to charge patients with deductibles & coinsurance. Now they are blocking coupons from being applied to deductibles.

4

19

45

Stephen J. Ubl

@steveubl

4 years

Just a few years ago, the devastating Ebola epidemic & fear associated with it swept the globe. To this day Ebola continues to take far too many lives. But thanks to innovative biopharmaceutical researchers, we now have a vaccine to prevent Ebola - a huge win for public health.

6

9

47

Stephen J. Ubl

@steveubl

3 years

Less than one year after the genetic sequence of the coronavirus, we are turning a corner in this pandemic w/ the first @US_FDA EUA for a #COVID19 vaccine. This stunning scientific achievement from @pfizer / @BioNTech_Group will help bring us back to normal.

0

8

46

Stephen J. Ubl

@steveubl

7 years

We take drug pricing concerns seriously, want to work w/ @POTUS , Congress on mkt-based reforms to impr access to & affordability of meds 3/3

1

42

Stephen J. Ubl

@steveubl

6 years

We need to move away from a convoluted system of list prices, net prices & rebates to one that that measures value through the eyes of the patient and enables the private sector to develop new and better ways to pay for medicines. #POLITICOHealth

4

19

38

Stephen J. Ubl

@steveubl

6 years

Read @phillydotcom ’s profile of @Merck CEO Ken Frazier. There’s no better principled, inspiring leader in Philadelphia to be chosen as Inquirer Business Hall of Fame Icon. Congratulations on your hard work and success, Ken.

Merck CEO Ken Frazier rose from humble beginnings in North Philly to run a big pharma company |...

After Ken Frazier's 8 years as CEO, the board recently extended his contract. He heads a storied research company but faces challenges especially on drug pricing.

www.inquirer.com

2

16

40

Stephen J. Ubl

@steveubl

2 years

@JAMAInternalMed These massive markups mean many hospitals are earning more revenue on medicines than the biopharmaceutical companies that developed them.

2

9

40

Stephen J. Ubl

@steveubl

6 years

There is indeed a robust pipeline of cancer medicines and vaccines in development - over 1,100 at this moment - and 85% of them are potential first-in-class. Great news in this report. #GoBOLDLY

PhRMA's new report counts each cancer drug in the US pipeline, which has now swelled to over 1,000...

Cancer drugs are crowding in to an already cramped pipeline this year, with hundreds of immuno-oncology hopefuls now taking a shot at clinical testing. That’s according to a new cancer report from...

endpts.com

2

19

34

Stephen J. Ubl

@steveubl

6 years

Despite what critics say, @ExpressScripts data confirms competitive market drives spending growth down (1.5% in 2017 – the lowest in 25 years). $ESRX

4

17

33

Stephen J. Ubl

@steveubl

6 years

New analysis from @IHSMarkit shows sharing negotiated discounts at the pharmacy counter could save a senior with diabetes more than $350 annually.

Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than...

Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually.

phrma.org

3

7

35

Stephen J. Ubl

@steveubl

7 years

It’s almost here. We have a big, bold announcement coming tomorrow. Stay tuned.

2

29

35

Stephen J. Ubl

@steveubl

6 years

. @TheEconomist : Which firms profit most from America’s health-care system: It is not pharmaceutical companies

4

18

35

Stephen J. Ubl

@steveubl

7 years

Sending our condolences to the family of @CurrentIncurSci . Dr. Tom was a dedicated researcher who always put patients first in his quest to cure cancer. He will be greatly missed. #GoBoldly

3

17

32

Stephen J. Ubl

@steveubl

3 years

I am excited about how our industry is working together to end #COVID19 . Examples of these great collaborative efforts include recent news about @Sanofi and @Novartis working with @Pfizer to increase production of Pfizer/BioNTech’s COVID-19 vaccine.

Novartis says it's ready to pitch in on manufacturing rivals' COVID-19 vaccines, diagnostics

Right after Sanofi stepped in to help produce Pfizer/BioNTech coronavirus vaccines in Europe, Novartis is exploring whether | Right after Sanofi stepped in to help produce Pfizer/BioNTech coronavirus...

www.fiercepharma.com

0

5

33

Stephen J. Ubl

@steveubl

4 years

Our industry is working around the clock to beat coronavirus. Read about a new commitment from @PhRMA and @IAmBiotech members to eradicate the virus.

America’s biopharmaceutical companies are working around the clock to beat coronavirus

PhRMA and BIO underscored the industry’s commitment to finding solutions to prevent, diagnose and treat those with COVID-19, a disease caused by a novel strain of coronavirus. The investments...

phrma.org

3

16

32

Stephen J. Ubl

@steveubl

6 years

. @JoeBiden is right - courage & hope is key. @MeghanMcCain , we’ve seen amazing developments & treatments for cancer patients and we’re not about to stop the fight to end cancer. Our thoughts and prayers are with your dad.

1

5

34

Stephen J. Ubl

@steveubl

3 years

From my family to yours, wishing everyone a safe and happy holiday season.

1

0

33

Stephen J. Ubl

@steveubl

6 years

Recent comments from the CEO of generic manufacturer Nostrum Laboratories are tone deaf, particularly as patients are increasingly facing affordability challenges in the marketplace.

5

24

32

Stephen J. Ubl

@steveubl

5 years

We congratulate @SGottliebFDA for his exemplary leadership at @US_FDA . He should be commended for his efforts to streamline the development & approval process of groundbreaking new treatments that are transforming the lives of patients & increasing competition in the market.

0

3

32

Stephen J. Ubl

@steveubl

5 years

59 new treatments were approved by the @US_FDA in 2018 - the majority of them (42) were first approved in the United States. When biopharmaceutical companies are encouraged to innovate, American patients benefit. Read more by @AndrewPowaleny .

Putting 2018 medicine approvals in context

the U.S. Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved a record number of novel new medicines with 59 new molecular entities (NMEs). CDER met all its...

phrma.org

2

18

32

Stephen J. Ubl

@steveubl

1 year

For another year in a row, cancer death rates continue to decline due in large part to advances in treatment. With an estimated 3.8M lives saved since 1991, our industry remains committed to continuing this progress. #WorldCancerDay

1

9

31

Stephen J. Ubl

@steveubl

6 years

We were deeply saddened to learn that Dan Best passed away. Our thoughts and prayers are with his family, colleagues and all who love him. Dan was an amazing person of exceptional talent and he will truly be missed.

0

6

31

Stephen J. Ubl

@steveubl

6 years

Happy Independence Day. To those who are serving overseas and around the world - and to all who have sacrificed to provide us the freedoms we enjoy today, thank you! #July4th2018 🇺🇸

0

12

31

Stephen J. Ubl

@steveubl

4 years

This week, @AmericanCancer found we had the largest single-year drop in cancer mortality ever recorded between 2016 - 2017. That’s thanks in part to innovation occurring at labs, like the one at @KitePharma I visited earlier this week.

4

8

32